$LTRN Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-284 for Mantle Cell Lymphoma at the Society of Hematologic Oncology Annual Meeting

on September 23, 2022 News and Tags: , , , with 0 comments
Time:
8:50 AM
Symbol:
LTRN
Source:
Business Wire
Read more

$LTRN Lantern Pharma to Host Virtual KOL Webinar on the Treatment of Pediatric Cancers During Childhood Cancer Awareness Month, featuring Peter Houghton, Ph.D.

on September 19, 2022 News and Tags: , , , with 0 comments
Time:
8:50 AM
Symbol:
LTRN
Source:
Business Wire
Read more

$LTRN Lantern Pharma Reports Second Quarter 2022 Financial Results and Operational Highlights

on August 8, 2022 News and Tags: , , , with 0 comments
Time:
4:01 PM
Symbol:
LTRN
Source:
Business Wire
Read more

$LTRN Lantern Pharma to Report Second Quarter 2022 Operating & Financial Results on August 8th, 2022 at 4:30 p.m. ET

on August 1, 2022 News and Tags: , , , with 0 comments
Time:
7:00 AM
Symbol:
LTRN
Source:
Business Wire
Read more

$LTRN Lantern Pharma Receives FDA Authorization to Initiate its Phase 2 Clinical Trial, Harmonicâ„¢, for LP-300 in Never Smokers with Non-Small Cell Lung Cancer

on July 14, 2022 News and Tags: , , , with 0 comments
Time:
7:00 AM
Symbol:
LTRN
Source:
Business Wire
Read more

$LTRN Lantern Pharma Enters into Strategic Collaboration with Deep Lens — Partnership Expected to Accelerate Enrollment in Upcoming Phase 2 Clinical Trial for Never-Smokers with Non-Small Cell Lung Cancer

on September 28, 2021 News and Tags: , , , with 0 comments
Time:
9:20 AM
Symbol:
LTRN
Source:
PR Newswire
Read more

$LTRN Lantern Pharma to Participate in Two Upcoming Virtual Investor Conferences During September

on September 7, 2021 News and Tags: , , , with 0 comments
Time:
9:02 AM
Symbol:
LTRN
Source:
PR Newswire
Read more